ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

GKOS vs LLY // OPERATING MARGIN

Glaukos Corporation (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: GKOS 3 — LLY 11
▲ OPERATING MARGIN LEADER: LLY
operating-margins
-39.30%
operating-margins
40.21%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GKOS VS. LLY) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC GKOS LLY SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 55.70% 83.64% -27.94 LLY /gross-margins <GO>
Return on Invested Capital (ROIC) -13.70% 32.36% -46.06 LLY /roic <GO>
EV/EBITDA & P/E Valuation — 36.4x — TIE /valuation <GO>
Free Cash Flow Yield -0.16% 2.30% -2.46 LLY /fcf-yield <GO>
Operating Margin ACTIVE -39.30% 40.21% -79.51 LLY /operating-margins <GO>
Net Profit Margin -37.00% 31.90% -68.90 LLY /net-margins <GO>
Revenue Growth (YoY) 32.30% 45.51% -13.21 LLY /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.49% -0.49 LLY /dividend-safety <GO>
Altman Z-Score & Debt/Equity 26.00 9.29 +16.71 GKOS /balance-sheet <GO>
Piotroski F-Score Quality 5/9 9/9 -4.00 LLY /piotroski-score <GO>
Options Implied Move & Put/Call Skew 7.00% 6.77% +0.23 LLY /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 82.6 77.9 +4.70 GKOS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.04 0.51 +0.53 GKOS /macro-sensitivity <GO>
Forward P/E Multiple 34.0x 26.3x +7.75 LLY /forward-pe <GO>
Enterprise Scale & Market Cap $14.35B $1.33T -$1.32T LLY /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR GKOS REV LLY REV GKOS GROSS % LLY GROSS % GKOS FCF LLY FCF
FY 2025 $507.4M $65.18B 55.7% 83.0% -$22.5M $16.81B
FY 2024 $383.5M $45.04B 75.5% 81.3% -$67.6M $8.82B
FY 2023 $314.7M $34.12B 44.0% 79.3% -$71.9M $4.24B
FY 2022 — $28.54B — 76.8% — $7.59B
FY 2021 — $28.32B — 74.2% — $7.37B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GKOS // BETA 1.04
LLY // BETA 0.51